Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1985 Jul;20(1):61–66. doi: 10.1111/j.1365-2125.1985.tb02799.x

Caffeine disposition in obesity.

D R Abernethy, E L Todd, J B Schwartz
PMCID: PMC1400629  PMID: 4027137

Abstract

Caffeine pharmacokinetics were studied in 16 obese (mean +/- s.e. mean body weight; 110 +/- 8 kg; % ideal body weight (IBW); 186 +/- 14%) and 23 normal body weight (64 +/- 3 kg; 103 +/- 3% IBW) subjects. Eight obese and four control subjects were cigarette smokers. After abstaining from caffeine for 48 h and an overnight fast, each subject ingested 162 mg caffeine orally. Concentrations of caffeine were measured in plasma samples obtained during the 24 h following the dose and pharmacokinetic variables were determined. The apparent volume of distribution was increased markedly in obese subjects (69.9 +/- 5.9 vs 43.6 +/- 2.8 l; P less than 0.001) in the absence of any change in oral clearance (135 +/- 14-obese vs 112 +/- 12 ml/min; NS), resulting in a trend toward increased elimination half-life (7.05 +/- 1.08-obese vs 5.40 +/- 0.40 h; NS). Apparent volume of distribution correlated well with percent IBW (r = 0.65; P less than 0.001). Caffeine clearance, suggested as a measure of in vivo cytochrome P-448 activity in humans, was not altered in obesity. In contrast, the extent of caffeine distribution increased in direct relation to body weight. If caffeine is used therapeutically, the loading dose should be calculated as a function of total body weight. Since clearance of caffeine is not related to body weight, these data indicate that a chronic dosing regimen to maintain a given plasma caffeine concentration should not be altered due to obesity.

Full text

PDF
61

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abernethy D. R., Greenblatt D. J., Divoll M., Harmatz J. S., Shader R. I. Alterations in drug distribution and clearance due to obesity. J Pharmacol Exp Ther. 1981 Jun;217(3):681–685. [PubMed] [Google Scholar]
  2. Abernethy D. R., Greenblatt D. J., Divoll M., Shader R. I. Prolonged accumulation of diazepam in obesity. J Clin Pharmacol. 1983 Aug-Sep;23(8-9):369–376. doi: 10.1002/j.1552-4604.1983.tb02750.x. [DOI] [PubMed] [Google Scholar]
  3. Abernethy D. R., Greenblatt D. J., Divoll M., Smith R. B., Shader R. I. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clin Pharmacokinet. 1984 Mar-Apr;9(2):177–183. doi: 10.2165/00003088-198409020-00005. [DOI] [PubMed] [Google Scholar]
  4. Aldridge A., Neims A. H. The effects of phenobarbital and beta-naphthoflavone on the elimination kinetics and metabolite pattern of caffeine in the beagle dog. Drug Metab Dispos. 1979 Nov-Dec;7(6):378–382. [PubMed] [Google Scholar]
  5. Aldridge A., Parsons W. D., Neims A. H. Stimulation of caffeine metabolism in the rat by 3-methylcholanthrene. Life Sci. 1977 Oct 1;21(7):967–974. doi: 10.1016/0024-3205(77)90263-6. [DOI] [PubMed] [Google Scholar]
  6. Aranda J. V., Cook C. E., Gorman W., Collinge J. M., Loughnan P. M., Outerbridge E. W., Aldridge A., Neims A. H. Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. J Pediatr. 1979 Apr;94(4):663–668. doi: 10.1016/s0022-3476(79)80047-5. [DOI] [PubMed] [Google Scholar]
  7. Aranda J. V., Gorman W., Bergsteinsson H., Gunn T. Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. J Pediatr. 1977 Mar;90(3):467–472. doi: 10.1016/s0022-3476(77)80718-x. [DOI] [PubMed] [Google Scholar]
  8. Baecke J. A., Burema J., Deurenberg P. Body fatness, relative weight and frame size in young adults. Br J Nutr. 1982 Jul;48(1):1–6. doi: 10.1079/bjn19820081. [DOI] [PubMed] [Google Scholar]
  9. Becker A. B., Simons K. J., Gillespie C. A., Simons F. E. The bronchodilator effects and pharmacokinetics of caffeine in asthma. N Engl J Med. 1984 Mar 22;310(12):743–746. doi: 10.1056/NEJM198403223101202. [DOI] [PubMed] [Google Scholar]
  10. Blanchard J., Mohammadi J. D., Conrad K. A. Improved liquid-chromatographic determination of caffeine in plasma. Clin Chem. 1980 Aug;26(9):1351–1354. [PubMed] [Google Scholar]
  11. Blanchard J. Protein binding of caffeine in young and elderly males. J Pharm Sci. 1982 Dec;71(12):1415–1418. doi: 10.1002/jps.2600711229. [DOI] [PubMed] [Google Scholar]
  12. Blanchard J., Sawers S. J. Comparative pharmacokinetics of caffeine in young and elderly men. J Pharmacokinet Biopharm. 1983 Apr;11(2):109–126. doi: 10.1007/BF01061844. [DOI] [PubMed] [Google Scholar]
  13. Blanchard J., Sawers S. J. The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol. 1983;24(1):93–98. doi: 10.1007/BF00613933. [DOI] [PubMed] [Google Scholar]
  14. Brazier J. L., Ritter J., Berland M., Khenfer D., Faucon G. Pharmacokinetics of caffeine during and after pregnancy. Dev Pharmacol Ther. 1983;6(5):315–322. doi: 10.1159/000457332. [DOI] [PubMed] [Google Scholar]
  15. Broughton L. J., Rogers H. J. Decreased systemic clearance of caffeine due to cimetidine. Br J Clin Pharmacol. 1981 Aug;12(2):155–159. doi: 10.1111/j.1365-2125.1981.tb01194.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Desmond P. V., Patwardhan R., Parker R., Schenker S., Speeg K. V., Jr Effect of cimetidine and other antihistaminics on the elimination of aminopyrine, phenacetin and caffeine. Life Sci. 1980 Apr 14;26(15):1261–1268. doi: 10.1016/0024-3205(80)90071-5. [DOI] [PubMed] [Google Scholar]
  17. Forbes G. B., Welle S. L. Lean body mass in obesity. Int J Obes. 1983;7(2):99–107. [PubMed] [Google Scholar]
  18. Frisancho A. R., Flegel P. N. Relative merits of old and new indices of body mass with reference to skinfold thickness. Am J Clin Nutr. 1982 Oct;36(4):697–699. doi: 10.1093/ajcn/36.4.697. [DOI] [PubMed] [Google Scholar]
  19. Gal P., Jusko W. J., Yurchak A. M., Franklin B. A. Theophylline disposition in obesity. Clin Pharmacol Ther. 1978 Apr;23(4):438–444. doi: 10.1002/cpt1978234438. [DOI] [PubMed] [Google Scholar]
  20. Grant D. M., Tang B. K., Kalow W. Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther. 1983 Mar;33(3):355–359. doi: 10.1038/clpt.1983.45. [DOI] [PubMed] [Google Scholar]
  21. Jung D., Mayersohn M., Perrier D., Calkins J., Saunders R. Thiopental disposition in lean and obese patients undergoing surgery. Anesthesiology. 1982 Apr;56(4):269–274. doi: 10.1097/00000542-198204000-00007. [DOI] [PubMed] [Google Scholar]
  22. Jusko W. J., Gardner M. J., Mangione A., Schentag J. J., Koup J. R., Vance J. W. Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. J Pharm Sci. 1979 Nov;68(11):1358–1366. doi: 10.1002/jps.2600681106. [DOI] [PubMed] [Google Scholar]
  23. Knutti R., Rothweiler H., Schlatter C. Effect of pregnancy on the pharmacokinetics of caffeine. Eur J Clin Pharmacol. 1981;21(2):121–126. doi: 10.1007/BF00637512. [DOI] [PubMed] [Google Scholar]
  24. Levi L. The effect of coffee on the function of the sympatho-adrenomedullary system in man. Acta Med Scand. 1967 Apr;181(4):431–438. doi: 10.1111/j.0954-6820.1967.tb07260.x. [DOI] [PubMed] [Google Scholar]
  25. Mitchell M. C., Hoyumpa A. M., Schenker S., Johnson R. F., Nichols S., Patwardhan R. V. Inhibition of caffeine elimination by short-term ethanol administration. J Lab Clin Med. 1983 Jun;101(6):826–834. [PubMed] [Google Scholar]
  26. Newton R., Broughton L. J., Lind M. J., Morrison P. J., Rogers H. J., Bradbrook I. D. Plasma and salivary pharmacokinetics of caffeine in man. Eur J Clin Pharmacol. 1981;21(1):45–52. doi: 10.1007/BF00609587. [DOI] [PubMed] [Google Scholar]
  27. Rohrbaugh T. M., Danish M., Ragni M. C., Yaffe S. J. The effect of obesity on apparent volume of distribution of theophylline. Pediatr Pharmacol (New York) 1982;2(1):75–83. [PubMed] [Google Scholar]
  28. Wietholtz H., Voegelin M., Arnaud M. J., Bircher J., Preisig R. Assessment of the cytochrome P-448 dependent liver enzyme system by a caffeine breath test. Eur J Clin Pharmacol. 1981;21(1):53–59. doi: 10.1007/BF00609588. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES